Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in advanced hepatocellular carcinoma
NCT01658878Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2012
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of nivolumab in hepatocellular carcinoma (HCC) (9 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events, Serious Adverse Events and 5 more. Started Oct 2012; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01658878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658878.